Price Action Don’t Lie: How Analysts Feel About Axovant Sciences Ltd After Today’s Significant Decline?

Price Action Don't Lie: How Analysts Feel About Axovant Sciences Ltd After Today's Significant Decline?

The stock of Axovant Sciences Ltd (NYSE:AXON) is a huge mover today! The stock decreased 2.10% or $0.3 during the last trading session, hitting $14. About 347,590 shares traded hands. Axovant Sciences Ltd (NYSE:AXON) has risen 11.02% since February 29, 2016 and is uptrending. It has outperformed by 0.60% the S&P500.
The move comes after 6 months negative chart setup for the $1.41B company. It was reported on Oct, 1 by We have $13.16 PT which if reached, will make NYSE:AXON worth $84.60 million less.

Analysts await Axovant Sciences Ltd (AXON) to report earnings on November, 7. They expect $-0.39 EPS, down 225.00% or $0.27 from last year’s $-0.12 per share. After $-0.38 actual EPS reported by Axovant Sciences Ltd for the previous quarter, Wall Street now forecasts 2.63% negative EPS growth.

Axovant Sciences Ltd (NYSE:AXON) Ratings Coverage

Out of 4 analysts covering Axovant Sciences (NYSE:AXON), 3 rate it a “Buy”, 1 “Sell”, while 0 “Hold”. This means 75% are positive. Axovant Sciences has been the topic of 4 analyst reports since September 25, 2015 according to StockzIntelligence Inc. The firm has “Overweight” rating given on Thursday, October 22 by Piper Jaffray. Chardan Capital Markets maintained Axovant Sciences Ltd (NYSE:AXON) on Friday, September 25 with “Sell” rating. The stock has “Outperform” rating given by Leerink Swann on Tuesday, June 7. The stock of Axovant Sciences Ltd (NYSE:AXON) has “Buy” rating given on Friday, January 8 by H.C. Wainwright.

According to Zacks Investment Research, “Axovant Sciences Ltd. is a biopharmaceutical company which focuses on the acquisition, development and commercialization of therapeutics for the treatment of neurodegenerative disorders. Its product candidate includes RVT-101 which is in different clinical trial for the treatment of Alzheimer’s disease and other forms of dementia. Axovant Sciences Ltd. is based in Hamilton, Bermuda.”

More notable recent Axovant Sciences Ltd (NYSE:AXON) news were published by: which released: “Why Axovant Sciences Ltd (AXON), Jabil Circuit, Inc. (JBL) and Virgin America …” on September 22, 2016, also with their article: “Axovant Sciences Ltd. Announces Pricing of Initial Public Offering” published on June 11, 2015, published: “Axovant Sciences Receives FDA Fast-Track Designation for Intepirdine as an …” on September 26, 2016. More interesting news about Axovant Sciences Ltd (NYSE:AXON) were released by: and their article: “Axovant Sciences Ltd. Announces Completion of Initial Public Offering and Full …” published on June 16, 2015 as well as‘s news article titled: “Why Axovant Sciences Skyrocketed 56% in November” with publication date: December 03, 2015.

AXON Company Profile

Axovant Sciences Ltd., formerly Roivant Neurosciences Ltd., incorporated on October 31, 2014, is a clinical-stage biopharmaceutical firm focused on acquiring, developing and commercializing therapeutics for the treatment of dementia. The Firm focuses on developing a pipeline of product candidates to address the cognitive, functional and behavioral aspects of dementia and related neurological disorders.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Leave a Comment